Earnings Season| Skyrizi has been the top performer at ABBV

$AbbVie(ABBV)$ ABBV Announces European Commission Approval of Skyrizi for the treatment of moderate to severe active Crohn's Disease (CD)

• Third indication in EU
• First specific IL-23 inhibitor for the CD treatment
• Same indication approved in June by the FDACrohn's Disease per ABBV was a $14 Billion global market in 2020Skyrizi has been the top performer at ABBV
At Q3 this year
• run rate of $5+ B annual revenue
• 75% TTM growth rate
• 9% of ABBV revenuehttps://twitter.com/DividendWave/status/1595374317466185734

# US Stocks Opportunities

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment14

  • Top
  • Latest
  • liewtc60
    ·2022-11-24
    ABBV is a good dividend growth stock that give positive returns to shareholders with improved EPS and PER.
    Reply
    Report
  • SirBahamut
    ·2022-11-24
    Thanks for sharing!
    Reply
    Report
  • SnailWalker
    ·2022-11-24
    [Salute] [Salute]
    Reply
    Report
  • Mtortise
    ·2022-11-24
    Ok
    Reply
    Report
  • Zambuk
    ·2022-11-24
    .
    Reply
    Report
  • YQ123
    ·2022-11-24
    great
    Reply
    Report
  • stsockli
    ·2022-11-24
    great 👍
    Reply
    Report
  • 壮志高飞
    ·2022-11-24
    [smile]
    Reply
    Report
  • aunteenat
    ·2022-11-24
    ok
    Reply
    Report
  • leolow84
    ·2022-11-24
    like
    Reply
    Report
  • JonLucky
    ·2022-11-24
    cool
    Reply
    Report
  • tamira
    ·2022-11-24
    👍
    Reply
    Report
  • j up p
    ·2022-11-24
    yes
    Reply
    Report
  • ericbie
    ·2022-11-24
    [smile]
    Reply
    Report